Elsevier

Neuroscience

Volume 68, Issue 4, October 1995, Pages 1189-1198
Neuroscience

Research paper
Effects of l-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum

https://doi.org/10.1016/0306-4522(95)00120-8Get rights and content

Abstract

The cellular expression of the genes encoding the neuropeptides enkephalin and substance P were examined in the caudate nucleus and putamen of parkinsonian 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated cynomolgus monkeys by in situ hybridization using radioactive antisense oligonucleotides coupled with computer-assisted image analysis. Behavioural evaluation of the animals revealed two levels of motor impairment; one group moderately impaired and the other severely disabled. A marked increase in the cellular content of preproenkephalin A messenger RNA was observed in medium-sized (106 ± 9 μm2) cells in the caudate-putament of all MPTP animals when compared with controls, the increase being greatest in the most severely impaired animals. By contrast, a marked reduction in the cellular abundance of preprotachykinin gene expression was detected in striatal cells (101 ± 16 μm2) of these same MPTP animals. These changes in neuropeptide gene expression were not associated with a change in the density (approximately 10 cells per mm2) of messenger RNA-expressing cells. l-DOPA treatment of two of the severely-impaired MPTP monkeys resulted in a dissociation of expression of these two genes: the cellular abundance of preproenkephalin A remained elevated whilst preprotachykinin levels were normalized and comparable with controls. No change in the cellular abundance of preprotachykinin messenger RNA was observed in cells of the insular cortex or a small discrete population of large cells (208 ± 27 μm2) in the ventral putamen.

These results demonstrate that MPTP treatment of primates results in a marked potentiation in preproenkephalin messenger RNA coupled with an attenuation in preprotachykinin messenger RNA in the dopamine-denervated caudate-putamen. l-DOPA therapy given on an intermittent schedule reverses the decrease in preprotachykinin messenger RNA, but fails to reverse the increase in preproenkephalin messenger RNA in the same animal. These observations suggest that a dissociation of the activity of these two neuropeptide systems may underlie the improvement in motor skill that accompanies dopamine replacement therapy and that this dissociation may well be instrumental in the long-term complications associated with l-DOPA therapy.

References (60)

  • T.M. Engber et al.

    l-DOPA replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats

    Brain Res.

    (1991)
  • G. Fenelon et al.

    Topographic distribution of pallidal neurones projecting to the thalamus in macaques

    Brain Res.

    (1990)
  • C.R. Gerfen

    Substance P (neurokinin-1) receptor mRNA is selectively expressed in cholinergic neurons in the striatum and basal forebrain

    Brain Res.

    (1991)
  • W.C. Graham et al.

    Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced Parkinsonism

    Brain Res.

    (1993)
  • R. Guevara Guzman et al.

    Effect of substance P on acetylcholine and dopamine release in the rat striatum: a microdialysis study

    Brain Res.

    (1993)
  • K.A. Harrington et al.

    Dopamine D1 receptor, D2 receptor, preproenkephalin A and preprotachykinin gene expression in human control and schizophrenic caudate nucleus: a quantitative cellular in situ hybridisation study

    (1995)
  • M.T. Herrero et al.

    Does neuromelanin contribute to the vulnerability of catecholaminergic neurones in monkeys intoxicated with MPTP?

    Neuroscience

    (1993)
  • M.T. Herrero et al.

    Effect of l-DOPA on pallidal GABAergic neurones in parkinsonian syndromes

    Neurology

    (1995)
  • J. Jolkkonen et al.

    Altered enkephalin and substance P gene expression in the caudate-putamen of MPTP-treated marmosets

    Soc. Neurosci. Abstr.

    (1993)
  • B.J. Morris et al.

    Regulation of striatal prodynorphin mRNA levels of the raphe-striatal pathway

    Molec. Brain Res.

    (1988)
  • L.K. Nisenbaum et al.

    Temporal dissociation between changes in striatal enkephalin and substance P messenger RNAs following striatal dopamine depletion

    Neuroscience

    (1994)
  • M. Noda et al.

    Isolation and structural organization of the human preproenkephalin gene

    Nature

    (1982)
  • G.J. Nutt

    Levodopa-induced dyskinesia: review, observations, and speculations

    Neurology

    (1990)
  • L.D. Selemon et al.

    Islands and striosomes in the neostriatum of the rhesus monkey: non-equivalent compartments

    Neuroscience

    (1994)
  • R. Shigemoto et al.

    Immunocytochemical localisation of rat substance P receptor in the striatum

    Neurosci. Lett.

    (1993)
  • D.L. Somers et al.

    Striatal preprotachykinin and preproenkephalin mRNA levels and the levels of nigral substance P and pallidal Met5-enkephalin depend on corticostriatal axons that use the excitatory amino acid neurotransmitters aspartate and glutamate: quantitative radio-immunocytochemical and in situ hybridization evidence

    Molec. Brain Res.

    (1990)
  • O. Strada et al.

    Decreased choline acetyltransferase mRNA expression in the nucleus basalis of Meynert in Alzheimer's disease: an in situ hybridisation study

  • P. Voorn et al.

    Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions

    Brain Res.

    (1987)
  • P.D. Walker et al.

    Serotonin regulation of tachykinin biosynthesis in the rat neostriatum

    Brain Res.

    (1991)
  • B.K. Yamamoto

    Dopaminergic modulation of glutamate release in striatum as measured by microdialysis

    J. Neurochem.

    (1992)
  • Cited by (0)

    View full text